Crystalline 3-O-fucosyllactose Purification via Phase Transition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The synthesis and purification of 3-O-fucosyllactose, an important human milk oligosaccharide, are challenging and costly due to its amorphous form, which affects its properties and makes commercialization difficult.
Innovation Solution
Obtaining crystalline 3-O-fucosyllactose by drying syrupy forms under high vacuum or converting amorphous forms to crystalline using antisolvents, followed by classical crystallization with seeding in alcoholic solvent systems, resulting in high-purity polycrystalline material with specific X-ray powder diffraction patterns and thermal stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If 3-FL is synthesized by enzymatic, biotechnological and chemical processes, then 3-FL can be obtained, but it is isolated as an amorphous material which is costly to purify
Solution Approach 1:
The patent applies phase transition by converting amorphous 3-FL to crystalline form through controlled crystallization processes. The invention describes methods to induce crystallization from amorphous material by adjusting temperature, solvent composition, and using seeding techniques, thereby transforming the physical state and improving purification efficiency
Solution Approach 2:
The patent employs parameter changes by systematically varying crystallization conditions including temperature gradients, solvent ratios (alcoholic solvents mixed with water), pH levels, and concentration to achieve reliable crystallization of 3-FL. These parameter optimizations enable consistent formation of crystalline material suitable for cost-effective purification
2Manufacturing precision
If 3-FL is isolated from human milk by chromatographic procedures, then pure 3-FL can be obtained, but the process is very costly and complicated
Solution Approach 1:
The patent applies extraction by removing 3-FL from complex mixtures through selective crystallization. By inducing crystallization of 3-FL from solution while leaving other components in solution, the method extracts pure crystalline 3-FL without requiring complex chromatographic separation procedures
Solution Approach 2:
The patent replaces complex mechanical chromatographic systems with a simpler crystallization-based purification approach. Instead of using sophisticated chromatographic equipment and procedures, the invention uses controlled crystallization followed by simple filtration to achieve high purity 3-FL
3Stability of the object's composition
If amorphous 3-FL is used, then synthesis is simpler, but it lacks thermodynamic stability and has poor solubility properties
Solution Approach 1:
The patent applies preliminary action by preparing amorphous 3-FL as an intermediate step and then systematically converting it to the stable crystalline form. The invention describes preliminary drying of syrupy material followed by controlled crystallization to achieve the thermodynamically stable crystalline state with improved properties
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a cost-effective and scalable process for obtaining high-purity crystalline 3-O-fucosyllactose suitable for nutritional and pharmaceutical applications, enhancing its stability and solubility properties.
Implementation Method 1
crystalline 3-FL can be obtained when 3-FL in syrupy form is dried under high vacuum for prolonged time
Implementation Method 2
amorphous/precipitated 3-FL can be converted to crystalline material when suspended and stirred in bad solvent(s) for some time
Implementation Method 3
it can be used as seeding crystals for classical crystallization from solvent system, preferably those comprising an alcoholic solvent
Data Source
AI summary
Crystalline 3-O-fucosyllactose, useful in a pharmaceutical composition and a nutritional formulation, is disclosed.